PresbyLASIK using the SUPRACOR algorithm and micromonovision in presbyopic myopic patients: 12 months visual and refractive outcomes

To evaluate the visual and refractive outcomes for presbyopia and myopia treatment using the Teneo 317 M2 platform and the myopic SUPRACOR algorithm.Percy Military Hospital and private Laser Victor Hugo Center, France.Observational retrospective nonrandomized study.Fifty eyes (25 patients) treated with bilateral myopic SUPRACOR and micromonovision using the Teneo 317 M2 platform and followed up for 12 months. Study outcomes included binocular and monocular visual acuities (without correction for distance and near vision), the spherical equivalent, predictability, stability, safety, optical aberrations and complications.The mean age was 50.6 ± 2.7 years and the mean preoperative spherical equivalent was -2.6 ± 1.4 diopters. At 12 months postoperatively, the mean binocular UDVA was 0.02 ± 0.03 logMAR and 24 patients (96%) achieved an acuity of 20/25 or better. Binocular UNVA was equal to Jaeger 1 in 18 patients (72%), and Jaeger 2 or better in 23 patients (92%). Twelve eyes (24%) had lost 1 Snellen line and 1 eye (2%) had lost 2 Snellen lines of monocular CDVA. No cases required retreatment; however, one eye (2%) underwent revision surgery, due to diffuse lamellar keratitis.Our study suggests that SUPRACOR using the Teneo 317 M2 platform is a safe and effective technique for myopia and presbyopia treatment. SUPRACOR is therefore a viable alternative to monovision for presbyopia and myopia. However, a careful patient selection is essential to satisfy realistic expectations.